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doi:10.1016/j.ejvs.2011.03.011Abstract Aim: The study aimed to evaluate vascular access site complications (ASCs) after
percutaneous interventions (PIs) in our institution for changes in annual incidence and surgical
management after increased usage of a vascular closure device (VCD; in all cases: Angioseal).
Material and Methods: All patients who underwent repair of arterial pseudo-aneurysms or
access site stenosis/occlusion leading to leg ischaemia (LI) or new-onset disabling claudication
(CI) after PIs between 2001 and 2008 were included. Annual rates of procedures and methods
of repair of ASC were evaluated.
Results: After a total of 58 453 PIs, 352 patients (0.6%) were operated on for: pseudo-aneurysms
(n Z 300; 0.51%); and local stenosis/occlusion leading to LI/CI (n Z 52; 0.09%). Numbers
increased significantly with more widespread VCD use: group A (2001e2004: 2860 VCDs; 28 284
PIs; 10.1%): n Z 132 (0.47%); and group B (2005e2008: 11,660 VCDs; 30,169 PIs; 38.6%):
n Z 220 (0.73%) (p < 0.001). In contrast to similar rates of pseudo-aneurysms (group A:
nZ 124; 0.44%; group B: nZ 176; 0.58%; not significant), a significant increase of operations
for local stenoses/occlusionswas seenwithwidespread VCDuse: nZ 8 versus nZ 44 (p< 0.001).
Conclusions: In the era of VCDs, complications are rare. However, use of these devices is not
without complications, and may require complex reconstructions.
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Closure Devices and Access Site Complications 231Vascular access site complications (ASCs) remain a concern
of percutaneous interventions (PIs). Therefore, manage-
ment of the arterial puncture site is an important issue in
endovascular procedures. Local control after PI is tradi-
tionally accomplished by manual compression. Since the
mid-1990s, a number of different vascular closure devices
(VCDs) were introduced to replace manual compression at
the arterial puncture site. The primary advantage attrib-
uted to VCDs is a shortened period to haemostasis and
avoidance of prolonged immobilisation so that earlier
patient discharge can be achieved.16 However, recently
published large meta-analyses analysing VCDs and ASCs
failed to demonstrate benefits of VCD use.1,5,7 Moreover,
ASCs were reported as a consequence of VCD use, including
local stenosis/occlusion at the access site and pseudo-
aneurysms due to device dislocation.813
To analyse and compare ASCs after PIs in years with
sporadic VCD use versus the era with more widespread VCD
use, we evaluated data in our institution, a high-volume
university hospital. Our primary interest was focussed on
incidence and results of operative repair of pseudo-
aneurysms and local stenoses or occlusions at the punc-
ture site leading to limb ischaemia (LI) or new-onset severe
claudication (CI).
Patients and Methods
Patients who underwent surgical repair of arterial ASCs
after transfemoral or transbrachial catheter interventions
between 2001 and 2008 in our institution were identified
by searching our institutional diagnosis registry. Patients
were included for further analysis, if they had surgical
repair of arterial pseudo-aneurysms at the puncture site
or access site stenoses/occlusions leading to LI or new-
onset disabling CI after PI. The medical records of all
individuals were reviewed. Data collection included
demographic parameters, details of coronary and vascular
intervention such as the use of an arterial closure system,
clinical presentation, diagnosis and therapy of the ASC.
Outcome was evaluated including complications (death,
limb loss, need for re-operation or re-intervention and
need for transfusion), and length of hospital stay. Annual
rates of surgical procedures and methods of repair of ASC
were analysed. Annual numbers of VCDs used were esti-
mated on the basis of yearly purchase lists. Patients were
grouped by the years 2001e2004 (group A; sporadic use of
VCD) and 2005e2008 (group B; more widespread use of
a collagen-plug based VCD; in all cases: Angioseal, St.
Jude Medical, St. Paul, Minnesota, USA), and, for
comparison of both groups, the chi-square test was used.
In addition, Bonferroni correction for multiple testing was
applied.
Results
A total of 58,453 PIs were performed in our institution
between 2001 and 2008 (group A, 2001e2004: n Z 28 284;
group B, 2005e2008: nZ 30 169). Surgical repair of arterial
ASCswas indicated in 352 patients (0.6%) (194 female;median
age: 67.3 years, range: 5.1e89.3 years) for: repair of pseudo-
aneurysm (nZ 300; 0.51%); and acute LI or new-onset severeCI caused by stenosis or occlusion at the access site (nZ 52;
0.087%). Annual numbers of PIs and numbers/rates of opera-
tions are summarised in Table 1. As shown, there were only
slight fluctuations of the annual numbers of PIs performed,
with lowest numbers in 2001 (nZ 6482) and highest in 2004
(n Z 7834). When numbers/rates of operations for ASCs in
years with sporadic VCD use (group A) and with frequent VCD
use (group B)were compared, therewas a significant increase
in the era of more widespread VCD use (group A: n Z 132;
0.47%; group B: nZ 220; 0.73%; p< 0.001). This increase was
caused by a more than fivefold increment in the number of
patients presenting with acute LI or new-onset severe CI due
to stenosis or occlusion at the access site (group A: n Z 8;
0.028%; group B: nZ 44; 0.146%; p< 0.001). By contrast, the
frequency of operations for pseudo-aneurysms was similar in
both time periods (group A: nZ 124; 0.44%; group B: nZ 176;
0.58%; not significant).
For closure of the arterial puncture site, a VCD (in all
cases: Angioseal) had been used in 2860 of 28,284 patients
(10.1%) in group A and in 11 660 of 30 169 patients (38.6%) in
group B (p < 0.001). In general, no VCDs were used for
brachial access. Annual numbers of procedures with and
without VCD use and operations in group A and B are sum-
marised in Tables 2 and 3. In patients without VCDs, the
numbers/rates of operations for pseudo-aneurysms (group
A: n Z 120; 0.5% of 25 424 PIs; group B: n Z 111; 0.6% of
18 509) and local stenosis/occlusion leading to LI/CI (group
A: n Z 4; 0.02% of 25 424 PIs; group B: n Z 10; 0.05% of
18,509) were similar. In patients with VCDs, operations for
pseudo-aneurysms (group A: nZ 4; 0.1% of 2860 PIs; group
B: n Z 65; 0.6% of 11,660) and local stenosis/occlusion
leading to LI/CI (group A: nZ 4; 0.1% of 2860 PIs; group B:
n Z 34; 0.3% of 11,660) increased with widespread use of
VCDs. This wasmainly caused by a significant increase in the
rate of operations for local stenoses and occlusions in
patients with VCD use (with VCD: 38 of 14,520 patients
(0.26%); without VCD: 14 of 43,933 patients (0.03%);
p < 0.001).
ASCs were located in the femoral (n Z 338; 96%) or
brachial artery (nZ 14; 4%). The arterial puncture sites, as
identified from the operation reports, were as follows: iliac
(n Z 18), common femoral (n Z 244), profunda femoris
(n Z 21), superficial femoral (n Z 45), their combination
(nZ 10) and brachial (nZ 14). Surgical repair of ASCs was
performed after previous unsuccessful thrombin injection
for treatment of pseudo-aneurysms in a group of 87
patients (29% of 300). Arterial repair included simple
sutures for oversewing of arterial defects (n Z 287; 82%),
patch angioplasty (n Z 51; 14%), interposition grafts
(n Z 4; 1%) or other techniques such as thrombectomy
(n Z 10; 3%). Whereas patients with puncture site defects
leading to pseudo-aneurysms were repaired mainly by
simple stitches (n Z 287 of 300; 95.7%), patients with
stenoses or occlusions needed more complex arterial
repair, such as patch angioplasties (39 of 52; 75%) or graft
interpositions (nZ 3; 6%). When patients with and without
VCD use are considered (see Table 4), only 9.4% of patients
without VCD had repair other than simple oversewing
stitches, whereas, in patients with VCDs, this rate was
39.3% (p < 0.001; Fisher’s exact test; Table 4). This indi-
cates that VCD-associated ASCs need more complex
procedures for arterial repair.
Table 1 Annual number of percutaneous interventions (PI total) and annual numbers/rates of surgical repair indicated for
access site complications (ASCs). OPZ operation; PsAZ pseudo-aneurysm; LIZ limb ischemia caused by stenosis/occlusion at
access site; CI Z severe claudication caused by stenosis/occlusion at access site; years 2001e2004: no use of VCDs; years
2005e2008: frequent use of VCDs.
PI total [n] All OP [n] All OP [%] PsA [n] PsA [%] LI or CI [n] Li or CI [%]
2001 6482 41 0.63 41 0.63 0 0
2002 6836 36 0.53 34 0.50 2 0.029
2003 7132 28 0.39 26 0.36 2 0.028
2004 7834 27 0.34 23 0.29 4 0.051
2001 to 2004 28,284 132 0.47 124 0.44 8 0.028
2005 7651 61 0.80 44 0.58 17 0.222
2006 7484 53 0.71 39 0.52 14 0.187
2007 7380 50 0.68 42 0.57 8 0.108
2008 7654 56 0.73 51 0.67 5 0.065
2005 to 2008 30,169 220 0.73 176 0.58 44 0.146
Total 58,453 352 0.60 300 0.51 52 0.087
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Perioperative outcome within 30 days after surgery: Nine
patients died during the perioperative period (30-day
mortality: 2.5%). No early limb loss occurred within 30 days
after surgery for ASCs. A total of 50 re-operations were
performed in 32 patients (9% of 352), including 25 re-
operations for wound infection in 13 patients (4% of 352)
and 13 revisions for haematoma in 13 patients (4% of 352).
In the perioperative period, a group of 83 patients (23%)
required substitution of packed red blood cells. Median
length of hospital stay was 6 days (maximum: 73 days).Discussion
ASCs remain a concern of percutaneous interventions. Most
frequently, surgical repair of ASCs is indicated for pseudo-
aneurysms at the access site.1,5,7,14 In our analysis, repair of
ASCswasperformed ina totalof352 individuals (0.6%of58,453
patients undergoing PIs) including 300 pseudo-aneurysms
(0.51%). It is noteworthy that our pseudo-aneurysm rate ofTable 2 Annual number [n]/rates [%] of percutaneous interven
(VCD).
PI total [n] With VCD [n] W
2001 6482 0 0
2002 6836 220
2003 7132 1320 1
2004 7834 1320 1
2001 to 2004 28,284 2860 1
2005 7651 2260 2
2006 7484 2760 3
2007 7380 3590 4
2008 7654 3050 3
2005 to 2008 30,169 11,660 3
Total 58,453 14,520 20.51% is rather low when compared with other series. Large
studies in patients with VCD or manual compression detected
pseudo-aneurysm in up to 2% in diagnostic PIs and even higher
rates in therapeutic coronary interventions.1522
When our series is analysed, the introduction and
frequent use of a VCD after 2004 was not associated with
a reduction of surgical repairs of pseudo-aneurysms. The
fact that VCDs do not reduce the incidence of pseudo-
aneurysms after PIs is clearly supported by recently pub-
lished large meta-analyses.1,5,7,14 Biancari reviewed 31
prospectively randomised studies including 7528 patients:
when the patients were randomised to manual compression
or different VCDs, the risk to develop a pseudo-aneurysm
was similar in both treatment arms.1
Concerning arterial ischaemic complications due to
ASCs, namely new-onset claudication and acute LI, our data
strongly indicate that widespread use of a VCD is associated
with significantly higher complication rates; when
compared with the years with sporadic use of VCDs,
ischaemic complication rates increased from 0.028% to
0.146%. Furthermore, use of VCD itself was significantly
associated with higher ischaemic complication rates: 0.26%tions (PI) with and without use of a vascular closure device
ith VCD [%] Without VCD [n] Without VCD [%]
% 6482 100%
3.2% 6616 96.8%
8.5% 5812 81.5%
6.8% 6514 83.2%
0.1% 25,424 89.9%
9.5% 5391 70.5%
6.9% 4724 63.1%
8.6% 3790 51.4%
9.8% 4604 60.2%
8.6% 18,509 61.4%
4.8% 43,933 75.2%
Table 3 Annual number of operations (OP) (all; PsA Z pseudo-aneurysm; LI/CI Z limb ischemia or new-onset claudication
caused by stenosis/occlusion at access site) in patients with and without Vascular Closure Device (VCD) use.
All OP [n] OP for PsA [n] With VCD [n] Without VCD [n] OP for LI/CI [n] With VCD [n] Without VCD [n]
2001 41 41 0 41 0 0 0
2002 36 34 2 32 2 1 1
2003 28 26 0 26 2 0 2
2004 27 23 2 21 4 3 1
2001 to 2004 132 124 4 120 8 4 4
2005 61 44 2 42 17 12 5
2006 53 39 11 28 14 13 1
2007 50 42 28 14 8 6 2
2008 56 51 24 27 5 3 2
2005 to 2008 220 176 65 111 44 34 10
Total 352 300 69 231 52 38 14
Closure Devices and Access Site Complications 233in patients with VCD versus 0.03% in individuals without
VCD. Femoral artery stenosis/occlusion caused by VCDs was
described earlier.2329 Nevertheless, ischaemic complica-
tions due to ASCs are very uncommon. In Biancari’s meta-
anaylsis, there had been no ischaemic complication in the
pooled data of control groups in 2295 patients who under-
went manual compression, but eight events (0.3%) in 2598
individuals after VCD deployment.1
In our series, the only VCD used was the Angioseal
device, one of the most widely used VCDs. It consists of an
absorbable intravascular anchor, a small bovine plug and an
absorbable traction suture.8,14,20,3032 VCD failure in clin-
ical series was relatively uncommon, and occurred in 1e3%
of patients.3,11,3234 Device deployment in calcified vessels
was associated with higher complication rates, and VCD use
was discouraged in the external iliac artery or below the
femoral bifurcation, as well as in vessels <5 mm in diam-
eter.25,26,32,3539 In our retrospective data analysis, we
were unable to correlate ASCs to anatomic details of the
puncture site, as such documentation was insufficient or
unavailable from many patients’ charts retrospectively.
Nevertheless, strategies for prevention of ASCs should be
aimed at detection of such anatomic risk situations, for
example, pre-procedural duplex ultrasound for assessment
of the femoral arteries.
Do different VCDs perform differently? As there are
many different devices on the market, our data reporting
on Angioseal-associated complications may not reflect
complications associated with other VCDs. Nevertheless, it
is shown that major vascular complications can occur withTable 4 Overall number and rates of different types of arterial
three-fold increase in more complex operations (patch angioplast
9.4%; p < 0.001; Fisher’s Exact Test).
With VCD [n] With VCD
Simple Stitch 65 60.7
Patch Angioplasty 29 27.1
Graft Interposition 3 2.8
Other 10 9.4
Total 107all different VCDs. There is no large randomised study
aimed at comparison of different VCDs with each other.
However, a randomised study evaluated three different
VCDs in a total of 705 patients undergoing percutaneous
coronary interventions, and all VCDs tested had similar
surgical repair rates of approximately 1e2%.40 Similarly,
others used two different VCDs in comparison to manual
compression and, if major vascular end points are evalu-
ated, could not describe a superiority of a particular VCD in
most series.17,33,34,41,42
However, a VCD with reported higher complication rates
in patients undergoing percutaneous coronary interventions
was the first generation of the VasoSeal device, which was
modified thereafter.3,7,14 The question whether new-
generation VCDs e after revision and improvements e are
associated with fewer complications is discussed contro-
versially.1,3,18,43,44 Biancari evaluated the impact of tech-
nical improvements and a learning curve in VCD use: they
concluded that the trend towards increased risk for arterial
complications and need for vascular surgery was observed
also in the most recently published series.1
It is of particular concern that prospective studies on VCD
use are very heterogeneously performed. If they are aimed
at comparison of different VCDs, or comparison between
VCDs and manual compression, many of them are certainly
underpowered to detect differences in major vascular
complications requiring surgery. As shown in our retrospec-
tive analysis in more than 58,000 patients, repair of pseudo-
aneurysms is performed in approximately 1 out of 200
individuals, and arterial repair of ischaemia caused by ASCsrepair in patients with and without use of VCDs: A more than
y or graft interposition) was seen in the era of VCDs (29.9% vs.
[%] Without VCD [n] Without VCD [%]
222 90.6
22 9.0
1 0.4
0 0
245
234 J. Klocker et al.in 1 out of 1000. Consecutively, the analysis of low compli-
cation rates need larger studies than performed so far.
Several limitations have to be considered when our data
are analysed: Our data were collected retrospectively. Thus,
data collectionwas incomplete and could not include several
parameters thatmight have been of interest, such as the size
of the introducer sheet, antegrade versus retrograde arterial
punctures and different anticoagulation regimens. The
number of VCDs used was calculated on the basis of annual
purchase lists; however, those data may slightly differ from
the annual numbers of VCDs used. In addition, the decision to
use VCDs or not in the individual patient was not based on
randomisation, but on the investigator’s preference or risk
calculation, which could not be analysed retrospectively.
Only patients who underwent surgery were analysed, and
patients treated conservatively were not included. As
a consequence, the overall numbers/rates of ASCs might be
underestimated. Moreover, patients with ASCs after PIs
performed in our institution might have been operated on
elsewhere and, therefore, not included in our analysis;
however, the number of such cases is presumably low, as our
centre is the only large-volumehospital in this particular part
of our country, and almost exclusively performs PIs.
In summary, with the increase of percutaneous arterial
procedures, definitive control of the access site is an
ongoing problem. Although VCDs are associated with earlier
haemostasis and time to ambulation, their cost and
potential associated complications limit their use. ASCs
after use of VCDs are rare, but continue to occur with
especially ischaemic complications occurring at a higher
rate. As a consequence, in the era of VCDs, patient selec-
tion and monitoring for these infrequent but potentially
serious complications is essential.Conflict of Interest/Funding
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